Abstract:Melanoma is a malignant neoplasia of pigment-producing melanocytes notable for its ability to metastasize early during primary tumor growth. Melanomas display typically high mutation burden—a hallmark associated with immune checkpoint blockade therapy (ICBT) sensitivity—but can still evade ICBT. These melanoma phenotypes likely relate to embryonic neural crest cells, a population of cells from which melanocytes arise. For instance, BRAF inhibition-evading melanoma cells adopt neural crest-like states. However, the exact embryonic lineage underlying BRAFi resistance remains unknown as does its relationship with any neural crest-like states that underlie ICBT resistance. To discover such states, we used a mouse fluorescent reporter model of melanoblast development in which melanocyte-specific GFP is driven by the dopachrome tautomerase promoter (iDct-GFP). Embryonic day (E) 11.5 and 15.5 melanoblasts were isolated and sequenced using single-cell transcriptomics (scRNA-seq). These time-points enriched for cells migrating from the dermis to epidermis (at E11.5) or for cells colonizing the hair follicle (at E15.5). These characteristics could help metastatic progression, namely migration across the basement membrane in early invasive melanomas and colonization of metastatic sites. We classified these embryonic melanocytes and their precursors into multiple clusters which in turn were grouped into four key lineages: Neural Progenitor, Schwann Cell Progenitor (SCP), Mesencyhmal (Mes) and Melanocytes (Mel). To detect the presence of these states in tumors, we derived developmental gene modules (DGMs): sets of genes that were preferentially co-expressed in each embryonic cell state. DGMs stratified TCGA samples; SCP-high and Mes-high subtypes were associated with worse survival compared to Mel-high tumors. Moreover, SCP-high tumors had lower T cell infiltration, and were associated with higher NGFR expression, a known marker of ICBT resistance. High expression of SCP DGMs was associated with poor response to anti-PD1 ICBT. Targeting factors underlying the SCP state might therefore sensitize tumours to ICBT. Mes DGMs on the other hand were associated with targeted therapy resistance. Cross-referencing DGMs with published RNA-seq data from melanoma cell lines suggest that SCP and Mes DGMs are induced by pro-inflammatory cytokines secreted by immune cells in the tumor microenvironment. Together, these observations suggest that the SCP state is implicated in the phenomenon of inflammation-induced de-differentiation, a process by which melanomas are able to evade ICBT. Our identification of the SCP and Mes states, along with a deeper understanding of their transcriptional programs and signaling pathways, may reveal clinically actionable targets to disrupt immuno- or targeted-therapy resistance. Citation Format: Vishaka Gopalan, Chun Wai Wong, Chi-Ping Day, Eva Perez-Guijarro, Maxwell P. Lee, Yuhong Jiang, Howard H. Yang, Maira Alves-Constantino, Antonella Sassano, Cari Smith, Mark Simpson, Sung Chin, Jessica Ebersole, Charli Gruen, Emily Wu, Sridhar Hannenhalli, Adam Hurlstone, Glenn Merlino, Kerrie Marie. Single-cell transcriptional analysis of embryonic melanoblasts pinpoints embryonic cell states that underlie targeted therapy and immune checkpoint blockade resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB233.

Single-Cell RNA Sequencing Reveals Cellular Heterogeneity in an Acral Amelanotic Melanoma after Immunotherapy Treatment.

Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy

A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma

A single-cell atlas reveals tumor heterogeneity and immune environment of acral melanoma

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma

Abstract 867: Molecular and functional characterization of melanocyte subpopulations in human epidermis based on single-cell RNA sequencing

Whole Genome and RNA Sequencing Reveal the Distinct Genomic Landscape of Acral Melanoma.

Spatial transcriptomic analysis of amelanotic acral melanoma versus pigmented acral melanoma reveals distinct molecular determinants

Integration of Bulk RNA Sequencing and Single-Cell RNA Sequencing to Reveal Uveal Melanoma Tumor Heterogeneity and Cells Related to Survival

Single-cell RNA sequencing in melanoma: what have we learned so far?

Advancing immunotherapy for melanoma: the critical role of single-cell analysis in identifying predictive biomarkers

Abstract 2593: Spatial multi-omics profiling of tumor cell phenotypes in primary cutaneous melanoma at single-cell resolution

Genomic Heterogeneity and Branched Evolution of Early Stage Primary Acral Melanoma Shown by Multiregional Microdissection Sequencing.

Abstract LB233: Single-cell transcriptional analysis of embryonic melanoblasts pinpoints embryonic cell states that underlie targeted therapy and immune checkpoint blockade resistance

Single-cell RNA-sequencing analyses identify heterogeneity of CD8+ T cell subpopulations and novel therapy targets in melanoma

Integrative analysis of bulk and single-cell RNA-seq reveals the molecular characterization of the immune microenvironment and oxidative stress signature in melanoma

Abstract 6865: Single cell analysis of melanoma reveals a prognostic myeloid cell associated with survival in melanoma with brain metastases

Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Abstract 109: Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma